Welcome to our dedicated page for Vaso news (Ticker: VASO), a resource for investors and traders seeking the latest updates and insights on Vaso stock.
Vaso Corporation (OTCQX: VASO) generates a steady flow of news related to its activities in medical technology, healthcare IT, and professional sales services. The company describes itself as a diversified MedTech and information technology business with operations in managed IT systems and services, healthcare professional sales services, and proprietary medical devices, and its announcements reflect developments across these areas.
News items frequently cover quarterly and annual financial results, where Vaso reports revenue, gross profit, segment performance, and the use of non-GAAP measures such as Adjusted EBITDA. These releases often highlight contributions from its IT, professional sales service, and equipment segments, as well as trends in deferred revenue and subscription revenues.
Another key category of updates involves commercial partnerships and long-term agreements. For example, the company has announced multiple extensions of the sales representation agreement between its VasoHealthcare subsidiary and GE HealthCare. A December 2025 release described the fifth extension of this agreement, which continues VasoHealthcare’s exclusive sales representation of GE HealthCare diagnostic imaging and ultrasound products in certain U.S. market segments through December 31, 2030.
Vaso’s news flow also includes strategic transactions and corporate actions. In November 2025, the company announced an agreement, subject to certain conditions, to sell its VasoHealthcare IT Corp. subsidiary to Nano-X Imaging Ltd., following a strategic review of its lines of business. Other releases address executive leadership appointments, board roles, and shareholder communications such as CEO letters summarizing achievements and strategic priorities.
Investors and observers who follow VASO news can expect coverage of financial performance, segment updates, long-term sales agreements, divestitures, leadership changes, and shareholder meeting information, providing insight into how the company manages its diversified MedTech and IT portfolio.
Summary not available.
Vaso Corporation reported its annual financial results for 2022, achieving a record annual revenue of $80.0 million, a 5.9% increase from 2021. Annual net income rose to $11.9 million, up 95.7% year-over-year. The company highlighted strong performance in its professional sales service segment and improved operating results in the IT segment. However, the fourth-quarter revenue decreased by 4.2% compared to the prior year, attributed to lower revenues across all segments. Vaso ended the year with $20.3 million in cash and short-term investments and a significant increase in deferred revenue to $30.8 million.
Vaso Corporation reported a 5.9% growth in total revenue for fiscal year 2022, reaching $80.0 million, alongside a 149% leap in operating income to $7.9 million. Despite a 4.2% revenue decline in Q4 2022 to $23.5 million, driven by reduced IT segment revenue and equipment sales, net income surged to $8.2 million due to a $4.8 million tax benefit. The company boasts a solid financial standing with $20.3 million in cash and short-term investments and a historically high deferred revenue of $30.8 million. Looking ahead, Vaso anticipates recovery and growth in its IT and professional sales segments.
Vaso Corporation reported a net income of $2.5 million for Q3 2022, an increase from $0.7 million in Q3 2021, on revenues of $20.0 million, up from $18.4 million year-over-year. The professional sales services segment saw a 30% increase in revenue, contributing significantly to earnings. Cash and short-term investments rose to $18.7 million, up $12.0 million since the start of the year. Adjusted EBITDA increased to $2.8 million. Despite challenges from inflation and supply chain issues, management remains optimistic about future performance.
Vaso Corporation (OTCMKTS:VASO) has received approval to up-list from the OTC Pink Sheets to the OTCQB market, effective October 10, 2022. This transition enhances transparency and compliance, facilitating greater trading liquidity and visibility for the company. The CEO, Jun Ma, expressed optimism about showcasing Vaso to a broader investor audience. The company operates in diverse medical technologies, including managed IT services and proprietary medical devices. The up-listing is seen as a strategic move to increase shareholder value and market recognition.
Vaso Corporation reported second quarter 2022 revenue of $19.5 million, up 21% year-over-year, leading to net income of $1.5 million, compared to a loss of $0.9 million last year. Gross profit increased 31% to $11.3 million, driven by the professional sales service segment. SG&A expenses rose 5% to $9.6 million, while cash reserves improved to $15.4 million. Despite challenges in the IT and equipment segments, the company remains optimistic about navigating ongoing economic uncertainties.
Vaso Corporation (OTC PINK:VASO) reported Q1 2022 financial results, showing a 3.0% year-over-year increase in revenue to $17.0 million and a 14.1% increase in gross profit to $9.8 million. The operating loss decreased by 34.3% to $0.4 million. Total deferred revenue reached a record $27.0 million, up by $8.5 million year-over-year. Despite a decrease in IT and equipment segment revenues due to external factors, the company’s financial health remains strong with $13.1 million in cash as of May 6, 2022.
Vaso Corporation (OTC PINK:VASO) reported its financial results for the year ended December 31, 2021, achieving total revenue of $75.6 million, an 8.2% increase year-over-year. The company also posted an operating profit of $2.8 million, up 265%. The fourth quarter alone saw a 31.1% revenue increase to $24.5 million. Gross profit rose 11.8% to $43.1 million, while net income for the year reached $6.1 million. The company reduced its debt by $8.1 million and reported deferred revenue of $25 million, indicating positive future outlook.
Vaso Corporation reported a 6% year-over-year revenue increase for Q3 2021, reaching $18.4 million. The operating loss was reduced by 29% to approximately $0.6 million. Adjusted EBITDA stood at $1.4 million, a decline from $1.8 million in Q3 2020. Despite a rise in SG&A expenses by 12% to $9.5 million, net income fell to $0.7 million from $1.0 million in the same period last year. The company maintains a strong cash position with $5.4 million in operating cash flow in 2021.
Vaso Corporation (OTCMKTS:VASO) announced the extension of its sales representation agreement with GE Healthcare through December 31, 2026. This agreement, originally signed in 2010, allows VasoHealthcare to exclusively represent select GE Healthcare diagnostic imaging products across the contiguous United States. Vaso's president praised the partnership, highlighting the success built over 11 years due to GE's quality products and services. The extension emphasizes Vaso's commitment to its collaborative goals in the healthcare sector.